[Comparative investigations concerning osteotropic radiopharmaceuticals. III. Scanning with 18F and 99mTc-malignant diseases (author's transl)].
Total body scans under identical conditions and using 18F and 99mTc-EHDP were carried out in patients with known, or subsequently proven, metastases. There was no statistical evidence for any difference in the number of scintigraphically demonstrable lesions. Patients with internal prostheses who developed infections of the prosthesis show no significant difference in the uptake of either nucleid. Soft tissue lesions showed a significantly higher uptake of 99mTc-EHDP than of 18F. 18F can be replaced for nearly all problems by 99mTc-EHDP without loss of diagnostic information.
D000038:Abscess / Q000175:diagnosis; D001847:Bone Diseases / Q000175:diagnosis*; D001859:Bone Neoplasms / Q000175:diagnosis; D012968:Etidronic Acid; D005260:Female; D005461:Fluorine / Q000009:adverse effects / Q000378:metabolism; D006801:Humans; D007249:Inflammation / Q000175:diagnosis; D007595:Joint Prosthesis; D009362:Neoplasm Metastasis; D010000:Osteitis / Q000378:metabolism; D011868:Radioisotopes; D011877:Radionuclide Imaging / Q000379:methods*; D013667:Technetium / Q000378:metabolism
D011868:Radioisotopes; D005461:Fluorine; D013667:Technetium; D012968:Etidronic Acid
Vergleichende Untersuchungen mit osteotropen Radiopharmaka. III. Szintigraphie mit 18F und 99mTc-EHDP bei malignen und nichtmalignen Erkrankungen